IDH 突变型脑肿瘤利用 R-2-羟基戊二酸攻击巨噬细胞的阿喀琉斯之踵。
IDH-Mutant Brain Tumors Hit the Achilles' Heel of Macrophages with R-2-Hydroxyglutarate.
机构信息
Department of Molecular Cell Biology and Immunology, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam Institute for Infection and Immunity, Cancer Centre Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Department of Molecular Cell Biology and Immunology, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam Institute for Infection and Immunity, Cancer Centre Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
出版信息
Trends Cancer. 2021 Aug;7(8):666-667. doi: 10.1016/j.trecan.2021.06.003. Epub 2021 Jun 26.
Isocitrate dehydrogenase (IDH) mutations produce high levels of the 'oncometabolite' R-2-hydroxyglutarate (R-2-HG) and play a key role in the initiation and progression of glioma tumors in the brain. A recent study in Nature Cancer by Friedrich et al. describes how IDH-mutant-derived R-2-HG elicits an immunosuppressive phenotype in glioma-associated macrophages. As such, the authors uncovered a new vulnerability that can be exploited for therapy.
异柠檬酸脱氢酶（IDH）突变会产生高水平的“致癌代谢物”R-2-羟戊二酸（R-2-HG），并在脑胶质瘤肿瘤的发生和发展中起关键作用。弗里德里希等人在《自然癌症》杂志上的一项最新研究描述了 IDH 突变衍生的 R-2-HG 如何在胶质瘤相关巨噬细胞中引发免疫抑制表型。因此，作者揭示了一种新的脆弱性，可用于治疗。
Zotero 插件